VitalPatch Wins FDA Emergency Use Authorization for Cardiac Monitoring in COVID Patients

Hydroxychloroquine and chloroquine, used to treat some COVID-19 patients, are associated with risk of prolonged QT interval that can lead to life-threatening arrhythmias. VitalPatch allows clinicians to remotely and continuously monitor patients at risk of QT prolongation due to COVID-19 treatment.
VitalPatch is an FDA-approved device. Besides serving as a single-lead ECG, it monitors seven other physiological parameters continuously, including body temperature, heart rate, heart rate variability, respiratory rate, and blood oxygen saturation levels. It can also integrate with third-party devices to monitor blood pressure, weight, and oxygen saturation. According to the company, it is the first and only biosensor capable of monitoring such a broad set of patient vitals.
VitalPatch can be worn for up to seven days and is powered by a disposable zinc air battery with up to 168 hours of battery life. It measures 120 x 40 mm and is secured to the patient by a hydrocolloid adhesive.
“COVID-19 presents a myriad of symptoms and clinicians need access to medical devices that allow them to monitor and manage those symptoms in real-time in order to create the most appropriate treatment plans for each individual,” said Dr. Joe Roberson, Chief Medical Officer of VitalConnect, in a statement. “The enhancement of the VitalPatch receiving Emergency Use Authorization for QT-interval detection will enable this platform to further support clinicians who are on the frontlines of treating this virus.”
Flashbacks: VitalPatch Biosensor and VistaTablet Monitor: A Medgadget Review; VitalConnect Introduces Remote Arrhythmia Detection Using VitalPatch
Product Page: VitalPatch
Via: VitalConnect